Recombinant Human V-set domain-containing T-cell activation inhibitor 1(B7H4),partial

Code CSB-EP801822HUe0
Size US$1726
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names B7H4
Uniprot No. Q7Z7D3
Research Area Immunology
Alternative Names B7 family member, H4; B7 H4; B7 homolog 4; B7 superfamily member 1; B7 superfamily, member 1; B7-H4; B7h.5; B7h4; B7S1; B7x; BC032925; Immune costimulatory protein B7-H4; Immune costimulatory protein B7H4; MGC41287; PRO1291; Protein B7S1; RP11 229A19.4; T cell costimulatory molecule B7x; T-cell costimulatory molecule B7x; V set domain-containing T cell activation inhibitor 1; V-set domain-containing T-cell activation inhibitor 1; VCTN1; Vtcn1; VTCN1_HUMAN
Species Homo sapiens (Human)
Source E.coli
Expression Region 26-258aa
Target Protein Sequence IIGFGISGRHSITVTTVASAGNIGEDGILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQLLNSKA
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 52.6kDa
Protein Length Partial
Tag Info N-terminal GST-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation.
Gene References into Functions
  1. None of the genotype distributions showed a significant difference from the control group for the rs10801935 polymorphism. We conclude that B7-H4 has the potential to be a useful prognostic marker in urothelial carcinoma. PMID: 28425229
  2. B7-H4/NF-kappaB signaling is involved in the EMT and invasion of bladder cancer cells. PMID: 29391086
  3. The aim of the present work was to evaluate the effectiveness of anti-B7-H4-scFv-CH3 against tumors in vitro and in vivo. ScFv can inhibit signaling pathways to improve immunity by binding with the T lymphocyte negative co-stimulatory factor B7-H4. PMID: 30207312
  4. High B7-H4 expression is associated with phyllodes tumors. PMID: 30486739
  5. Studies suggest that V-set domain containing T cell activation inhibitor 1 protein (B7S1) may represent a very promising candidate to be targeted to treat various tumors. PMID: 30069671
  6. Human Immunodeficiency virus type-1 myeloid derived suppressor cells inhibit cytomegalovirus inflammation through IL-27 and B7-H4. PMID: 28338007
  7. High B7-H4 expression is associated with glioblastoma. PMID: 30159779
  8. Serum B7-H4 detection, either alone or in combination with carbohydrate antigen 125, has an acceptable value in the diagnosis of OC. PMID: 29970702
  9. the findings of this study suggested that B7-H4 may have the potential to be a valuable prognostic marker and a target for individualized therapies for gastric cancer PMID: 29436630
  10. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. PMID: 29235470
  11. B7-H3 protein is expressed in the majority of NSCLCs and is associated with smoking history. High levels of B7-H3 protein have a negative prognostic impact in lung carcinomas. Coexpression of B7-H3 with PD-L1 and B7-H4 is relatively low, suggesting a nonredundant biological role of these targets. PMID: 28539467
  12. When compared to early-stage lung adenocarcinoma, metastatic pleural adenocarcinoma possessed higher level of nuclei membranous B7-H4 and lower cytoplasmic B7-H4 expression. PMID: 28923053
  13. The decrease of B7-H4 expression in salivary glands of Sjogren's syndrome patients contributes to the defect of negatively regulating the inflammation caused by CD4(+) T cells. PMID: 28217953
  14. Preclinical investigation into B7-H4-specific chimeric antigen receptor (CAR) T cells, antibody-mediated blockade of B7-H4, and anti-B7-H4 drug conjugates has shown antitumor efficacy in mouse models. PMID: 28325750
  15. This meta-analysis demonstrated that high B7-H4 expression is an unfavorable prognostic factor in NSCLC. PMID: 28404927
  16. This meta-analysis clarified that high B7-H4 expression in tissue was significantly associated with poor survival in patients with solid tumors. PMID: 27058425
  17. in pulmonary adenocarcinoma presenting with SPN, nuclear membrane localization of B7-H4 within the tumor cells is associated with increased malignancy PMID: 27438152
  18. Study reportes that B7-H3 and B7-H4 are highly expressed in human esophageal cancer tissues and significantly associated with tumor invasion. PMID: 27764786
  19. Results revealed B7-H4 to be associated with poor prognosis in patients with pancreatic cancer liver metastasis. B7-H4 may promote pancreatic cancer metastasis. PMID: 27750217
  20. PD-L1, IDO-1, and B7-H4 are differentially expressed in human lung carcinomas and show limited co-expression. While PD-L1 and IDO-1 are associated with increased tumor-infiltrating lymphoycte and IFN-gamma stimulation, B7-H4 is not. PMID: 27440266
  21. B7-H4 activation on Mphis/microglia in the microenvironment of gliomas is an important immunosuppressive event blocking effective T-cell immune responses. PMID: 27001312
  22. Knockdown of B7-H4 significantly up-regulated 57 miRNAs and down-regulated 14 miRNAs. PMID: 29145206
  23. Increased serum levels of sB7-H4 in early pregnancy in premature rupture of the amniotic membranes cases may indicate the dynamics of the immune response at the feto-maternal interface and, thus, may serve as a predictive marker for this pregnancy complication. PMID: 27302185
  24. our study demonstrates a strong promoting role of B7-H4 in lung tumor growth, progression and metastasis PMID: 28061481
  25. results demonstrated for the first time that miR-125b-5p could regulate the inflammatory state of macrophages via directly targeting B7-H4 PMID: 28754594
  26. B7-H4 is highly expressed in pancreatic cancer, and is an independent predictor of poor prognosis. PMID: 28600225
  27. Evidence of associations between genotypes and Juvenile Idiopathic Arthritis were found for VTCN1, while VTCN1_rs2358820 GA was associated with Uveitis . PMID: 28145159
  28. B7-H4 is highly expressed in human OSCC tissue, and the B7-H4 expression level was associated with the clinicopathological parameters containing pathological grade and lymph node status. PMID: 27383830
  29. High B7-H4 expression is associated with non-Hodgkin lymphoma. PMID: 28246881
  30. B7-H4 is frequently expressed in ovarian serous carcinomas, especially high-grade serous carcinomas, and may represent a novel immunotherapeutic target in this cancer. PMID: 27349304
  31. While PD-L1 expression correlated with MSI and high grade endometrial tumors, B7-H4 expression was independent of grade, histology and immune cell infiltration. PMID: 28347512
  32. the present review highlights the therapeutic potential of targeting B7-H4 in cancer PMID: 28258701
  33. Survival rate of the patients with higher B7-H4 expression was significantly worse than that of the patients with lower B7-H4 expression. PMID: 28412458
  34. Study provides evidence that B7-H4 expression is present in cervical intraepithelial neoplasia and cervical cancer patients and suggests its involvement in cervical cancer progression. PMID: 28260085
  35. this review shows that targeting the B7-H4 molecule may provide a promising potential for anticancer immunotherapy PMID: 27258187
  36. Higher expression of HBx and B7-H4 was correlated with tumor progression of hepatitis B virus-hepatocellular carcinoma, suggesting that B7-H4 may be involved in facilitating HBV-related hepatocarcinogenesis. PMID: 27182163
  37. Aberrant expression of B7-H4 has been identified to correlate with the TNM stage, differentiation degree and lymph node metastasis in patients with HCC. PMID: 27840912
  38. B7-H4 may be overexpressed on the majority of cells in the IDC microenvironment, including macrophages. In vitro experiments revealed that M1 and M2 cells expressed B7-H4. Compared with M1 cells, M2 cells exhibited significantly higher expression levels of B7-H4. PMID: 27430170
  39. wortmannin and rapamycin inhibit B7-H4-mediated tumor immunoresistance through regulating B7-H4 subcellular distribution. Taken together, these results suggest that PI3K/Akt/mTOR inhibitors might be used for adjuvant therapy aimed at inhibition of immune evasion. PMID: 28064317
  40. Unstable cell surface antigens are not suitable as targets for ADCC, and we therefore performed an indirect ADCC-redirecting T-cell cytotoxicity assay to study B7-H4 using polyclonal anti-mouse IgG antibody-mediated linking. PMID: 27632942
  41. Knockdown of B7-H4 increased CD8+ T cell-mediated cytotoxicity in vitro. PMID: 27177355
  42. study provided the first evidence that B7-H4 facilitated esophageal squamous cell carcinoma cell proliferation through promoting IL-6/STAT3 positive loopback pathway activation PMID: 27088889
  43. B7H4 antigen is a negative prognostic marker for pancreatic cancer patients and also seems to express resistance of pancreatic cancer patients to chemotherapy with gemcitabine. PMID: 25924930
  44. B7-H3 and B7-H4 are involved in esophageal squamous cell carcinoma (ESCC) progression and development and their coexpression could be valuable prognostic indicators. PMID: 26411671
  45. study suggest that serum B7-H4 is an independent prognostic indicator for HCC and may be a promising biomarker for early diagnosis as well as disease prognosis of HCC. PMID: 26505457
  46. Data show that disrupted control of costimulation, evidenced by VTCN1 loss in both APCs and pancreatic islets, ultimately results in altered balance of control of immune responses. PMID: 26773144
  47. Studied VTCN1 gene polymorphisms in susceptibility to Breast Cancer. PMID: 25385143
  48. Data indicate that the diagnostic efficiency of V-set domain containing T cell activation inhibitor 1 (sB7-H4) combined carcinoembryonic antigen (CEA) was superior to either sB7-H4 or CEA. PMID: 26301886
  49. In human amniotic fluid stem cells, the negative co-stimulatory molecule B7H4 regulates low immunogenicity, which can provide a modest inflammatory reaction microenvironment for wound repair. PMID: 26101181
  50. In women who underwent elective cesarian section, a significant increase in sB7-H4 serum levels occurred postpartal, while in women who experienced spontaneous onset of labor, there were no differences between prepartal and postpartal levels. PMID: 25907449
  51. Low expression of VTCN1 inhibits the viability and metastasis of ovarian carcinoma. PMID: 26211593
  52. B7-H4 expressed is elevated in colorectal cancer tissues than in the adjacent normal tissues. B7-H4 siRNA effectively inhibited the proliferation at 24 h and 48 h, arrested cell cycle at G0/G1, and suppressed cell invasion and migration. PMID: 26078947
  53. our data suggest that the evaluation of B7-H4 expression in tissues and blood is a useful tool for predicting the progression of osteosarcoma and prognosis PMID: 25954746
  54. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity. PMID: 25527357
  55. In conclusion, measurement of sB7-H4 might be a useful diagnostic and prognostic value for malignant pleural effusion patients PMID: 25636447
  56. B7-H4 levels in hepatocellular carcinoma patients were significantly higher than that in healthy controls. High B7-H4 levels were correlated with tumor size, tumor invasion, tumor differentiation and tumor-node metastasis stage. PMID: 25963168
  57. B7-H4 is overexpressed in human cervical cancers, and it is associated with low numbers of infiltrating CD8+T-lymphocytes and correspondingly low interferon-gamma production. PMID: 25446402
  58. The crystal structure of the human B7x immunoglobulin variable (IgV) domain at 1.59 A resolution was determined and mapped the epitopes recognized by monoclonal antibodies. PMID: 25437562
  59. Study indicates that B7-H4 has the potential to be an independent prognostic indicator for urothelial cell carcinoma. PMID: 25400757
  60. Chromatin immunoprecipitation analysis demonstrated binding of hypoxia-inducible factor-1alpha (HIF-1alpha) to proximal hypoxia-response element (HRE) sites within the B7-H4 promoter in multiple myeloma cells and cancer cell lines. PMID: 25725157
  61. Over-expression of B7-H1 and B7-H4 has strong prognostic significance and promotes colorectal tumor tolerance. PMID: 25053455
  62. low expression of B7-H4 could serve as a candidate biomarker for predicting response to NACT and could provide favorable prognostic information in GC. PMID: 25260881
  63. High serum B7-H4 expression is associated with gastric cancer. PMID: 24947047
  64. The expression of B7-H4 molecule on immature BDCA-1(+) myeloid dendritic cells were significantly lower in umbilical cord blood of healthy neonates when compared with those cells in peripheral blood of healthy adults PMID: 23066977
  65. In type 1 diabetes, elevated blood sVTCN1 levels appeared early in the disease progression and correlated with the aggressive pace of disease PMID: 24848066
  66. High B7-H4 expression is associated with thyroid cancer progression PMID: 23803071
  67. Data suggest that B7-H4 pathway might play an important role in maintenance of beta-cell function, but its exact role remains to be explored. PMID: 24326367
  68. polymorphisms in the FGFR2 and B7H4 genes, which might be associated with breast cancer risk, have been evaluated for the first time in Turkish women with breast cancer. PMID: 24125968
  69. patients who overexpressed B7H4 had worse prognosis than the ones who did not in pancreatic cancer PMID: 24280570
  70. role in the pathological changes of rheumatoid synovium in rheumatoid arthritis progression PMID: 23973734
  71. VTCN1 rs10923223 and VTCN1 rs12046117 were associated with a remitting course of juvenile idiopathic arthritis. PMID: 24347572
  72. High B7-H4 expression is associated with uterine tumors. PMID: 24658839
  73. High B7-H1 and B7-H4 expressions were closely correlated with poor prognosis in patients with colorectal cancer. PMID: 23873101
  74. Loss of B7-H4 function prevents tumor growth through many processes, including the induction of apoptosis and inhibition of the Erk1/2 signaling pathway indicating that B7-H4 is a cancer promoter and a potentially important therapeutic target. PMID: 23660627
  75. B7-H4 wild-type confers chemoresistance activity to RCC cell lines including Caki-1 and ACHN. Our study provides a new insight into the functional implication of B7-H4 in its subcellular localization PMID: 23318460
  76. our findings showed that cell surface expression of B7-H4 occurs only in tumors in vivo and that antibody binding of B7-H4 could restore antitumor T-cell responses. PMID: 23722540
  77. B7-H4 expression in malignant tumors is useful for clinical diagnosis, and may provide a novel molecular target for cancer treatment.[review] PMID: 23147549
  78. B7x may enable metastasizing cancer cells to escape local antitumor immune responses through interactions with the innate and adaptive immune systems. PMID: 23455497
  79. A review of B7-H3 and B7-H4 immune molecules and the role their overexpression plays in ovarian cancer. PMID: 22910694
  80. study concludes B7-H4 negatively regulates T cell-mediated antitumour immunity in nonsmall-cell lung cancer PMID: 22613410
  81. The intensity of the suppressive profile of the cervical cancer microenvironment indicated by the presence of both RCAS1 and B7H4 on the front of the tumor and in the macrophages and fibroblasts infiltrating the cancer stroma PMID: 22530960
  82. intracellular B7-H4 appears to prevent Fas/FasL-mediated bile duct epithelial cell apoptosis during the progression of primary biliary cirrhosis PMID: 21120594
  83. These results indicate a novel genetic association with the VTCN1 region in rheumatoid arthritis susceptibility. PMID: 22323440
  84. paper summarizes the pertinent data on the inhibitory role of B7-H4 in antitumor immunity and its association with cancer progression and survival [review] PMID: 22013483
  85. B7-H4 expression significantly correlated with tumor stage; the 5-year survival rate was significantly lower in patients with high B7-H4 expression than in those with low B7-H4 expression PMID: 21748517
  86. expression levels of B7-H4 in tumors indicated that B7-H4 may be involved in tumor formation and development. PMID: 21190056
  87. The expression of OPN and B7-H4 increased in epithelial ovarian cancer. PMID: 20038306
  88. Evidence of B7-H4 expression on melanoma cells as a mechanism controlling tumor immunity which is associated with patients' survival. PMID: 21378130
  89. High B7-H4 is associated with esophageal squamous cell carcinoma progression. PMID: 21519829
  90. The expression of B7-H4 molecules on immature myeloid and lymphoid dendritic cells in cord blood of healthy neonates PMID: 21478111
  91. Human bone marrow mesenchymal stem cells highly express B7H4, which plays an important role in the suppressive effects of HBMSC on T cell proliferation. PMID: 19954668
  92. Expression of B7-H4 had no effect on effectiveness of cytokine-induced killer cells adoptive immunotherapy in patients with gastric cancer. PMID: 20499308
  93. B7-H4 was diffusely expressed in cytoplasm and/or membrane of the prostate cancer tissue; the expression was much higher than that in normal prostate tissue. PMID: 20731031
  94. High B7-H4 mRNA copies were associated with gastric cancer progression. PMID: 20872810
  95. High B7-H4 is associated with gastric cancer. PMID: 20725832
  96. Novel role of B7-H4 molecule in the suppressive effect of hBMSCs on T-cell activation and proliferation. PMID: 19788399
  97. B7-H4 directly promotes malignant transformation of ovarian cancer cell line. PMID: 19955922
  98. B7-H4 gene polymorphism may contribute to the sporadic breast cancer risk and prognosis in Chinese Han women. PMID: 19903360
  99. May participate in negative regulation of cell-mediated immunity in peripheral tissues PMID: 12818165
  100. Negative regulator of T cell activation. (B7S1) PMID: 12818166

Show More

Hide All

Subcellular Location Cell membrane, Single-pass type I membrane protein
Protein Families Immunoglobulin superfamily, BTN/MOG family
Tissue Specificity Overexpressed in breast, ovarian, endometrial, renal cell (RCC) and non-small-cell lung cancers (NSCLC). Expressed on activated T- and B-cells, monocytes and dendritic cells, but not expressed in most normal tissues (at protein level). Widely expressed, i
Database Links

HGNC: 28873

OMIM: 608162

KEGG: hsa:79679

STRING: 9606.ENSP00000358470

UniGene: Hs.546434

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1